RxDoctor Payments Data

Zune Liu, MD

Internal Medicine · Rowland Heights, CANPI 1619069838

Payments from drug & device makers

$15,608in general payments, 2019–2025

Across 467 payments — averaging $33.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$7K
  • Amgen$1K
  • AbbVie$1K
  • Lilly USA, LLC$883
  • GSK$850
  • Boehringer Ingelheim$737
  • plus $4K from 20 others

What the payments were for

  • Travel & lodging$140%
  • Food & beverage$15,588100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,608 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$120,201
Medicare patients
145
Services billed
1,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol93$85,065
JardianceEmpagliflozin89$73,597
TrulicityDulaglutide27$41,948
JanuviaSitagliptin Phosphate27$24,767
Diclofenac Sodium21$23,717
Cyclosporine26$21,696
RybelsusSemaglutide18$20,196
VascepaIcosapent Ethyl31$19,822
Colesevelam Hcl41$18,798
VemlidyTenofovir Alafenamide13$16,574
Icosapent Ethyl46$14,734
EliquisApixaban25$14,637
TradjentaLinagliptin23$13,895
LinzessLinaclotide22$11,888
DapagliflozinDapagliflozin Propanediol16$7,608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$737$87,492112 claims
AstraZenecaFarxiga$6,580$85,06593 claims
Lilly USA, LLCTrulicity$883$41,94827 claims
MerckJanuvia$116$24,76727 claims
Novo NordiskRybelsus$599$20,19618 claims
GileadVemlidy$246$16,57413 claims
PfizerEliquis$17$14,63725 claims
AbbVieLinzess, Synthroid$1,029$12,37433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Rowland Heights

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →